As of Nov 19, 2026, 1 of 2 active firms rate BBDC a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BBDC EPS & revenue forecast
EPS · NEXT QUARTER
$0.26
Range $0.25 – $0.29 · 6 analysts · +5% YoY
Next period, 6 analysts expect Barings BDC Inc to earn $0.26 a share (range $0.25 – $0.29), versus $0.25 a year earlier. Full-year consensus is $1.04, growing to $1.03 the year after.
REVENUE · NEXT QUARTER
$65.4M
Range $61.6M – $67.2M · 6 analysts · -14% YoY
Revenue is expected to reach $65.4M (range $61.6M – $67.2M), -14.0% year-over-year. Full-year consensus is $255.1M, rising to $265.3M next year.
Top analysts covering Barings BDC Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BBDC.
#1
Finian O'Shea
Wells Fargo · Rank #131
Buy
$10.00+18.7% to target
Overall win rate
48%
+ Follow
#2
PJ
Paul Johnson
Keefe, Bruyette & Woods · Rank #148
Neutral
$9.50+12.8% to target
Overall win rate
38%
+ Follow
#3
Robert Dodd
Raymond James · Rank #207
Buy
$9.00+6.8% to target
Overall win rate
38%
+ Follow
#4
Casey Alexander
Compass Point · Rank #295
Buy
$10.75+27.6% to target
Overall win rate
31%
+ Follow
#5
RL
Ryan Lynch
Keefe, Bruyette & Woods
Neutral
$9.50+12.8% to target
Coverage
—
+ Follow
BBDC stock forecast FAQ
What is BBDC's average 12-month price target?+
The 2 active firms with a live target average $9.63 for Barings BDC Inc over the next 12 months, ranging from a $10.00 high to a $9.25 low, as of Nov 19, 2026.
Is BBDC stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BBDC?+
The Street-high target is $10.00 (Wells Fargo), and the Street-low is $9.25 (LUCID CAPITAL MARKETS). The average of all 2 active-firm targets is $9.63.
How many active Wall Street firms cover BBDC?+
2 active firms have a recognized rating on Barings BDC Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BBDC?+
Among analysts who currently cover BBDC, Finian O'Shea of Wells Fargo has the strongest overall Quantellect track record (Rank #131). Their current call is Buy with a $10.00 target.
What is Barings BDC Inc's projected EPS for next quarter?+
The consensus estimate is $0.26 per share (range $0.25 – $0.29) across 6 analysts. Full-year EPS is projected at $1.04, rising to $1.03 the following year.
How much revenue is Barings BDC Inc expected to report next quarter?+
Consensus revenue is $65.4M (range $61.6M – $67.2M). Full-year revenue is projected at $255.1M, growing to $265.3M next year.
Have analysts been upgrading or downgrading BBDC lately?+
As of Nov 19, 2026, 1 of 2 active firms rate BBDC a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BBDC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.